Patient-Driven Discontinuation of Tyrosine Kinase Inhibitors: Single Institution Experience

Leukemia and Lymphoma - United Kingdom
doi 10.3109/10428194.2013.831092
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Future Perspectives of Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia

Chemotherapy: Open Access
2017English

Patient Preferences for Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2012English

Personalized Therapy of Tyrosine Kinase Inhibitors

Japanese Journal of Clinical Pharmacology and Therapeutics
Pharmacology
2013English

Tyrosine Kinase Inhibitors for Diabetes

Science-Business eXchange
2008English

Utility of Patient-Specific Rod Instrumentation in Deformity Correction: Single Institution Experience

Spine Surgery and Related Research
OrthopedicsSurgeryNeurologySports Medicine
2020English

Tyrosine Kinase Inhibitors in Lung Cancer

Hematology/Oncology Clinics of North America
OncologyHematology
2012English

Small Molecule FLT3 Tyrosine Kinase Inhibitors

2012English

Tyrosine Kinase Inhibitors in Advanced Thyroid Cancer

Journal of the Siena Academy of Sciences
2012English

Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer

Oncologist
Cancer ResearchMedicineOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy